BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jiangsu Hengrui Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jiangsu Hengrui Pharmaceuticals's
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06015048-2207@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT06015048)
DESCRIPTION:Pyrotinib\, phase 1/2.\nStudy: A Trial of SHR-A1811 Combined Wi
 th Other Antitumor Therapies in Advanced Solid Tumors.\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06015048
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06737731-11119@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SHR-1681: Phase 1/2 readout est. (NCT06737731)
DESCRIPTION:SHR-1681\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase I
 /II Clinical Study of SHR-1681 for Injection in Patients With Advanced Sol
 id Tumors\nEstimated primary completion: November 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/shr-1681#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06737731
URL:https://assetmemo.bio/drug/shr-1681#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470983-452@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:HRS-1780: Phase 2 readout est. (NCT07470983)
DESCRIPTION:HRS-1780\, phase 2.\nStudy: A Phase II Clinical Study on the Ef
 ficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism\n
 Estimated primary completion: November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-1780#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07470983
URL:https://assetmemo.bio/drug/hrs-1780#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 i
 n Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05482568
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Adebrelimab\, phase 1/2\, Ovarian Cancer.\nStudy: A Clinical St
 udy of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurre
 nt Ovarian Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06840002
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568094-2727@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zeprumetostat: Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:Zeprumetostat\, phase 1/2\, Prostate Cancer.\nStudy: A Study of
  HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advance
 d Prostate Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zeprumetostat#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974929-9146@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-6209: Phase 1/2 readout est. (NCT06974929)
DESCRIPTION:SHR-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in
  Patients With Breast Cancer\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-6209#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06974929
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605222-11108@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-7787: Phase 1/2 readout est. (NCT06605222)
DESCRIPTION:SHR-7787\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Trial o
 f SHR-7787 Injection in Patients With Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-7787#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06605222
URL:https://assetmemo.bio/drug/shr-7787#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472725-489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-3167: Phase 2 readout est. (NCT07472725)
DESCRIPTION:SHR-3167\, phase 2\, Type 2 Diabetes.\nStudy: A Study Comparing
  Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-D
 ose Titration in Adults With Type 2 Diabetes Inadequately Controlled With 
 Oral Antihyperglycemic Agents\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07472725
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229950-30@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-7085: Phase 2 readout est. (NCT07229950)
DESCRIPTION:HRS-7085\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Clin
 ical Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetics of HRS
 -7085 Tablets in Patients With Inflammatory Bowel Disease\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/hrs-7085#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07229950
URL:https://assetmemo.bio/drug/hrs-7085#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820099-186@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT06820099)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Study on th
 e Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejecti
 on Fraction/Preserved Ejection Fraction Heart Failure and Obesity\nEstimat
 ed primary completion: December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06820099
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06915142-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06915142)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: A Phase II Clinical St
 udy of HRS-7058 in Combination With Antitumor Drugs in Patients With Advan
 ced Malignant Tumour\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06915142
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844474-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06844474)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844474
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688772-1489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07688772)
DESCRIPTION:SHR-1819\, phase 3.\nStudy: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic 
 Rhinitis\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/shr-1819#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07688772
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671379-2181@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT06671379)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-muta
 ted\, Advanced or Metastatic NSCLC\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06671379
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04957550-29@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:ivarmacitinib: Phase 3 readout est. (NCT04957550)
DESCRIPTION:ivarmacitinib\, phase 3.\nStudy: To Evaluate the Efficacy and S
 afety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis\nEstimat
 ed primary completion: 13 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ivarmacitinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04957550
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465563-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06465563)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: SHR-8068 in Combination With Ade
 brelimab\, Bevacizumab\, and Platinum-Based Chemotherapy as First-line Tre
 atment in Patients With Advanced Biliary Tract Cancer\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06465563
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413745-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06413745)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Clinical Stud
 y of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally
  Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06413745
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719530-31@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07719530)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: Phase II Clinical Trial
  of SHR-1139 Injection in Patients With Psoriasis\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07719530
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691804-9052@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT04691804)
DESCRIPTION:Fluzoparib\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Multicenter\, Randomized\, Double-Blind\, Placebo-Contr
 olled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and
  Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatme
 nt in Patients With Metastatic Castration-Resistant Prostate Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04691804
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT05424835)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Tria
 l of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Po
 sitive\, Unresectable and/or Metastatic Breast Cancer Subjects Previously 
 Treated With Trastuzumab and Taxane\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05424835
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746726-11078@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-9190: Phase 3 readout est. (NCT07746726)
DESCRIPTION:HRS-9190\, phase 3.\nStudy: Safety and Efficacy of HRS-9190 Com
 pared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adult
 s\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/hrs-9190#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07746726
URL:https://assetmemo.bio/drug/hrs-9190#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298772-11110@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SHR-4375: Phase 1/2 readout est. (NCT07298772)
DESCRIPTION:SHR-4375\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Study o
 f SHR-4375 Injection in Combination With Other Antitumor Therapies in Pati
 ents With Solid Tumors\nEstimated primary completion: January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/shr-4375#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07298772
URL:https://assetmemo.bio/drug/shr-4375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543224-1475@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:RSS0393: Phase 3 readout est. (NCT07543224)
DESCRIPTION:RSS0393\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomiz
 ed\, Double-Blind\, Placebo-Controlled Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaqu
 e Psoriasis.\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rss0393#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07543224
URL:https://assetmemo.bio/drug/rss0393#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136142-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07136142)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Phase I/II Clinical Study of
  FH-006 for Injection in Patients With Malignant Solid Tumors\nEstimated p
 rimary completion: February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07136142
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767513-1081@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07767513)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a
 ) and High Risk of Cardiovascular Events\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 67513
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059221-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT07059221)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A2102
  With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/
 MetastaticHead and Neck Squamous Cell Carcinoma Cancer\nEstimated primary 
 completion: March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07059221
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06520488-11069@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4642: Phase 1/2 readout est. (NCT06520488)
DESCRIPTION:HRS-4642\, phase 1/2.\nStudy: A Study of HRS-4642 in Combinatio
 n With Antineoplastic Agents in Advanced Solid Tumors\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hrs-4642#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06520488
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251595-29@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ivarmacitinib: Phase 2 readout est. (NCT07251595)
DESCRIPTION:ivarmacitinib\, phase 2.\nStudy: A Trial of SHR0302 Tablets and
  SHR0302 Base Gel in Patients With Non-segmental Vitiligo\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ivarmacitinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07251595
URL:https://assetmemo.bio/drug/ivarmacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269717-11075@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-1893: Phase 2 readout est. (NCT07269717)
DESCRIPTION:HRS-1893\, phase 2.\nStudy: A Phase II Clinical Trial of HRS-18
 93 in the Treatment of Heart Failure With Preserved Ejection Fraction\nEst
 imated primary completion: March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/hrs-1893#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07269717
URL:https://assetmemo.bio/drug/hrs-1893#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-11073@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-A1912: Phase 3 readout est. (NCT06929624)
DESCRIPTION:SHR-A1912\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx i
 n Diffuse Large B-cell Lymphoma\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1912#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06929624
URL:https://assetmemo.bio/drug/shr-a1912#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241416-11066@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rezvilutamide: Phase 3 readout est. (NCT07241416)
DESCRIPTION:Rezvilutamide\, phase 3\, Prostate Cancer.\nStudy: A Phase III 
 Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensit
 ive Prostate Cancer\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07241416
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06368167-2727@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT06368167)
DESCRIPTION:Zeprumetostat\, phase 2.\nStudy: A Phase II Study of SHR2554 in
  Patients With Relapsed or Refractory Follicular Lymphoma\nEstimated prima
 ry completion: April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zeprumetostat#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06368167
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354932-11089@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07354932)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Study of SHR-2173 in Participants
  With Primary IgA Nephropathy\nEstimated primary completion: April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07354932
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764628-11110@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:SHR-4375: Phase 1/2 readout est. (NCT06764628)
DESCRIPTION:SHR-4375\, phase 1/2.\nStudy: A Study of SHR-4375 in Subjects W
 ith Solid Tumors\nEstimated primary completion: May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/shr-4375#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06764628
URL:https://assetmemo.bio/drug/shr-4375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07458269-185@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ribupatide: Phase 2 readout est. (NCT07458269)
DESCRIPTION:ribupatide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With
  Obesity Who Do Not Have Diabetes\nEstimated primary completion: May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07458269
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06828354)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: A Stu
 dy of SHR-A1811 in Subjects With Ovarian Cancer\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06828354
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639347-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT06639347)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2\, Urothelial Carcinoma.\nStud
 y: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carc
 inoma\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06639347
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906731-11118@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-9803: Phase 1/2 readout est. (NCT06906731)
DESCRIPTION:SHR-9803\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Study o
 f SHR-9803 for Injection in Patients With Advanced Solid Tumors\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-9803#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06906731
URL:https://assetmemo.bio/drug/shr-9803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321951-1489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1819: Phase 2 readout est. (NCT07321951)
DESCRIPTION:SHR-1819\, phase 2\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 in Patients With Moderate-to-severe Atopic Dermatitis\nEstimated prim
 ary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07321951
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444684-31@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07444684)
DESCRIPTION:SHR-1139\, phase 2.\nStudy: A Study to Evaluate SHR-1139 Inject
 ion in Patients With Pyoderma Gangrenosum\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1139#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074446
 84
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229742-11089@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07229742)
DESCRIPTION:SHR-2173\, phase 2\, Lupus Nephritis.\nStudy: A Phase II Clinic
 al Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment
  of Patients With Active Lupus Nephritis\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722974
 2
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03980054-2207@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pyrotinib: Phase 3 readout est. (NCT03980054)
DESCRIPTION:Pyrotinib\, phase 3.\nStudy: A Study of Evaluating The Effects 
 Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast C
 ancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pyrotinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03980054
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123494-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06123494)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Gastric Cancer.\nStudy: SHR-A
 1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal J
 unction Adenocarcinoma After Progression on or After First-line Anti-HER2 
 Therapy-containing Regimen\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06123
 494
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758075-31@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07758075)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: A Phase II Clinical Stu
 dy to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients W
 ith Plaque Psoriasis\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/shr-1139#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07758075
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682272-2014@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Apatinib: Phase 2 readout est. (NCT07682272)
DESCRIPTION:Apatinib\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Trial 
 of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatm
 ent of Resectable Hepatocellular Carcinoma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07682
 272
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362355-11088@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SHR4640: Phase 2 readout est. (NCT07362355)
DESCRIPTION:SHR4640\, phase 2\, Gout.\nStudy: The Efficacy and Safety of SH
 R4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Pr
 imary Gout and Hyperuricemia\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr4640#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07362355
URL:https://assetmemo.bio/drug/shr4640#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497880-186@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:Safiglipron (HRS-7535): Phase 2 readout est. (NCT07497880)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 2\, Obesity.\nStudy: Efficacy an
 d Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Ove
 rweight With at Least 1 Weight-Related Comorbidity\nEstimated primary comp
 letion: 7 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07497880
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503888-2061@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Retlirafusp alfa: Phase 1/2 readout est. (NCT05503888)
DESCRIPTION:Retlirafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStu
 dy: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatm
 ent of Relapsed or Advanced Non-small Cell Lung Cancer\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05503888
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232576-31@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07232576)
DESCRIPTION:SHR-1139\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Stud
 y to Evaluate the Efficacy\, Safety and Pharmacokinetics of SHR-1139 in Pa
 tients With Moderate-to-severe Active Ulcerative Colitis\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232576
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289763-11089@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07289763)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: Phase II Randomized\, Open-label\, 
 Multicenter Clinical Study Evaluating the Safety\, Efficacy\, Pharmacokine
 tics\, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary
  Membranous Nephropathy\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07289763
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024173-11068@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07024173)
DESCRIPTION:HRS-8080\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Loc
 ally Advanced and Metastatic Breast Cancer\nEstimated primary completion: 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-8080
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 24173
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003321-2130@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07003321)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Ce
 ll Lung Cancer\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/hrs-4508#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07003321
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622342-11089@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07622342)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Phase II Study of SHR-2173 Inject
 ion in Patients With Myasthenia Gravis\nEstimated primary completion: Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0762
 2342
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653322-11077@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SHR-1703: Phase 3 readout est. (NCT06653322)
DESCRIPTION:SHR-1703\, phase 3.\nStudy: A Multi-centered，Randomized，Dou
 ble-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety o
 f SHR-1703 in Eosinophilic Asthma\nEstimated primary completion: September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1703#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06653322
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649292-11072@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:SHR-A1904: Phase 3 readout est. (NCT06649292)
DESCRIPTION:SHR-A1904\, phase 3.\nStudy: SHR-A1904 Compared With Investigat
 or's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line A
 dvanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma\
 nEstimated primary completion: 20 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/shr-a1904#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06649292
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-2130@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HRS-4508: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:HRS-4508\, phase 1/2.\nStudy: A Study of HRS-4508 in Combinatio
 n With Other Anti-tumor Therapy for Solid Tumor\nEstimated primary complet
 ion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hr
 s-4508#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07140393
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296341-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07296341)
DESCRIPTION:Adebrelimab\, phase 1/2\, Pancreatic Cancer.\nStudy: HRS-4642 C
 ombination With Other Antitumor Therapies in Patients With Solid Tumors\nE
 stimated primary completion: October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07296341
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920939-489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07920939)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Safe
 ty of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Ad
 ults With Insulin-Naive Type 2 Diabetes\nEstimated primary completion: Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07920
 939
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614984-1081@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:HRS-5346: Phase 2 readout est. (NCT07614984)
DESCRIPTION:HRS-5346\, phase 2\, Atherosclerotic Cardiovascular Disease.\nS
 tudy: A Clinical Trial of MK-7262 and Enlicitide in Participants With High
  Lipoprotein(a) (MK-7262-004)\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5346#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07614984
URL:https://assetmemo.bio/drug/hrs-5346#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11066@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Rezvilutamide: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:Rezvilutamide\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical
  Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Canc
 er\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/rezvilutamide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/rezvilutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923851-31@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07923851)
DESCRIPTION:SHR-1139\, phase 2.\nStudy: A Trial Evaluating the Efficacy and
  Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulos
 is\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/shr-1139#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07923851
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241767-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07241767)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Phase II Clinical Study of FH-
 006 for Injection Combined With Other Anticancer Therapies in Subjects Wit
 h Lung Cancer\nEstimated primary completion: November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07241767
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309055-1489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1819: Phase 3 readout est. (NCT07309055)
DESCRIPTION:SHR-1819\, phase 3\, Atopic Dermatitis.\nStudy: A Study of SHR-
 1819 Injection in Adolescents With Severe Atopic Dermatitis\nEstimated pri
 mary completion: November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-1819#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07309055
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555068-2130@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 1/2 readout est. (NCT06555068)
DESCRIPTION:HRS-4508\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Trial of HRS-6209 in Combination With Other Antitumor Therapies in B
 reast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced
  Solid Tumors\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-4508#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06555068
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754930-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06754930)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SHR-1826 for Injection in Combination With Other Antitumor Thera
 pies in Subjects With NSCLC\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06754930
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073534-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07073534)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Phase I/II Clinical Study of S
 HR-1501 Combined With Adbelizumab in Patients With Malignant Tumors\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07073534
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229586-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07229586)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Study of SHR-7367 With Anti-
 tumor Agents in Patients With Solid Tumors\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebre
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07229586
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-2061@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Stu
 dy of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 E
 xpression Gastric Cancer\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-2061@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Gastric Cancer.\nStudy: Safety and
  Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or
  Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retli
 rafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07102901
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232849-2130@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07232849)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hrs-4508#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232849
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751341-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07751341)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Clinical Study of SHR-9839 as 
 Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Ch
 emotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous 
 Cell Carcinoma\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07751341
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021963-11075@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-1893: Phase 2 readout est. (NCT07021963)
DESCRIPTION:HRS-1893\, phase 2\, Hypertrophic Cardiomyopathy.\nStudy: A Cli
 nical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic C
 ardiomyopathy\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hrs-1893#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07021963
URL:https://assetmemo.bio/drug/hrs-1893#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196774-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07196774)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoa
 djuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196774
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528027-186@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07528027)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Obesity.\nStudy: Phase III S
 tudy of HRS-7535 for Hypertension With Overweight or Obesity\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07528027
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418749-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07418749)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Cervical Cancer.\nStudy: A St
 udy of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients 
 With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Re
 current or Metastatic Cervical Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/notiretatug
 -rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07418749
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311694-11070@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4357: Phase 3 readout est. (NCT07311694)
DESCRIPTION:HRS-4357\, phase 3\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Phase III Study Comparing HRS-4357 With Novel Androgen Re
 ceptor Pathway Inhibitors in Patients With Progressive\, PSMA-Positive Met
 astatic Castration-Resistant Prostate Cancer\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-
 4357#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07311694
URL:https://assetmemo.bio/drug/hrs-4357#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913061-489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07913061)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: A Study Comparing
  SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently T
 reated With Basal Insulin\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07913061
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098403-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07098403)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Trial of SHR-1905 i
 n Subjects With Severe Uncontrolled Asthma\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcore
 kibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07098403
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic U
 rothelial Carcinoma\nEstimated primary completion: 31 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284875-185@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284875)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide in Participants Living With Obesity or Overweight With Weight-R
 elated Comorbidities Who Do Not Have Diabetes\nEstimated primary completio
 n: February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rib
 upatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07284875
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860750-111@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:vunakizumab: Phase 3 readout est. (NCT06860750)
DESCRIPTION:vunakizumab\, phase 3.\nStudy: A Trial of SHR-1314 Injection in
  Adult Patients With Active Non-radiographic Axial Spondyloarthritis\nEsti
 mated primary completion: February 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/vunakizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06860750
URL:https://assetmemo.bio/drug/vunakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299422-11089@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07299422)
DESCRIPTION:SHR-2173\, phase 2.\nStudy: A Study of SHR-2173 in Participants
  With Systemic Lupus Erythematosus\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07299422
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284979-185@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284979)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo 
 in Participants Living With Obesity Who Do Not Have Diabetes\nEstimated pr
 imary completion: March 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ribupatide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07284979
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Adebrelimab\, phase 3\, Breast Cancer.\nStudy: A Clinical Trial
  of SHR-A1811 in the Treatment of Triple-negative Breast Cancer\nEstimated
  primary completion: March 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07111832
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284901-185@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280327
DTEND;VALUE=DATE:20280328
SUMMARY:ribupatide: Phase 3 readout est. (NCT07284901)
DESCRIPTION:ribupatide\, phase 3\, Obesity.\nStudy: Efficacy and Safety of 
 Ribupatide Administered Once Weekly in Participants Living With Obesity or
  Overweight and Diabetes\nEstimated primary completion: 27 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07284901
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168200-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07168200)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Clinical Study of Ad
 ebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combin
 ed With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced
  Cervical Cancer\nEstimated primary completion: April 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07168200
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132827-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07132827)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: Efficacy and Safety of SHR-190
 5 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps\nEst
 imated primary completion: April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07132827
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796763-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07796763)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: A 
 Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chem
 otherapy and Bevacizumab as First-Line Treatment in Patients With Advanced
  Colorectal Cancer Expressing HER2\nEstimated primary completion: 1 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezet
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07796763
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704645-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07704645)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a 
 Treatment for Resectable Non-small Cell Lung Cancer\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 debrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07704645
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06778031-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06778031)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Clinical Study of SHR-A1811 in
  the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tra
 ct Cancer\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06778031
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally Re
 current/Metastatic Breast Cancer\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 497386
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441812-11077@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SHR-1703: Phase 2 readout est. (NCT06441812)
DESCRIPTION:SHR-1703\, phase 2.\nStudy: A Study to Evaluate the Long-term S
 afety\, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma P
 atients\nEstimated primary completion: September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/shr-1703#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06441812
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2061@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumo
 r Treatments in Non-small Cell Lung Cancer Subjects\nEstimated primary com
 pletion: October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07175220
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06335355-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06335355)
DESCRIPTION:Adebrelimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemot
 herapy in Advanced or Metastatic NSCLC Patients\nEstimated primary complet
 ion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06335355
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554509-1489@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:SHR-1819: Phase 2/3 readout est. (NCT06554509)
DESCRIPTION:SHR-1819\, phase 2/3.\nStudy: Clinical Study of the Efficacy an
 d Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis\nE
 stimated primary completion: October 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/shr-1819#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06554509
URL:https://assetmemo.bio/drug/shr-1819#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229612-11114@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:SHR-4298: Phase 1/2 readout est. (NCT07229612)
DESCRIPTION:SHR-4298\, phase 1/2.\nStudy: A Phase I/II Clinical Study of SH
 R-4298 Injection in Patients With Malignant Solid Tumors\nEstimated primar
 y completion: November 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/shr-4298#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07229612
URL:https://assetmemo.bio/drug/shr-4298#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389733-9146@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SHR-6209: Phase 1/2 readout est. (NCT07389733)
DESCRIPTION:SHR-6209\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of HRS-6208 in Combination With HRS-8080\, or Fulvestrant\, or
  Letrozole\, With or Without HRS-6209 in Patients With Advanced Unresectab
 le or Metastatic Breast Cancer\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/shr-6209#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07389733
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446153-11112@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8364: Phase 1/2 readout est. (NCT07446153)
DESCRIPTION:HRS-8364\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Clinica
 l Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/hrs-8364#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07446153
URL:https://assetmemo.bio/drug/hrs-8364#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895928-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06895928)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: A Trial of SHR-A2102 W
 ith Other Antitumor Therapies in Advanced Solid Tumors\nEstimated primary 
 completion: December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06895928
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07268040-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07268040)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Trial of SHR-7787 Injection Co
 mbined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07268040
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07798947-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07798947)
DESCRIPTION:Adebrelimab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Phase
  II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection 
 in Patients With LS-SCLC\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07798947
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230106-2727@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07230106)
DESCRIPTION:Zeprumetostat\, phase 2\, Prostate Cancer.\nStudy: A Study of S
 HR3680\, HS-20093 and SHR2554 in Subjects With Prostate Cancer\nEstimated 
 primary completion: December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/zeprumetostat#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07230106
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028281-11109@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SHR-4849: Phase 2 readout est. (NCT07028281)
DESCRIPTION:SHR-4849\, phase 2.\nStudy: A Trial of SHR-4849 Combined With O
 ther Antitumor Drugs in Patients With Malignant Solid Tumors\nEstimated pr
 imary completion: December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/shr-4849#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07028281
URL:https://assetmemo.bio/drug/shr-4849#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05979051-11077@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SHR-1703: Phase 2/3 readout est. (NCT05979051)
DESCRIPTION:SHR-1703\, phase 2/3\, Eosinophilic Granulomatosis with Polyang
 iitis.\nStudy: A Study to Evaluate the Efficacy and Safety of SHR-1703 in 
 Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/shr-1703#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05979051
URL:https://assetmemo.bio/drug/shr-1703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354022-9053@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dalpiciclib: Phase 3 readout est. (NCT07354022)
DESCRIPTION:Dalpiciclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalp
 iciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to
  Adjuvant Endocrine Therapy.\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dalpiciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07354022
URL:https://assetmemo.bio/drug/dalpiciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286032-11067@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hetrombopag: Phase 3 readout est. (NCT07286032)
DESCRIPTION:Hetrombopag\, phase 3\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine
  Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
  (ExCIT)\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07286032
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863167-2181@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 2 readout est. (NCT07863167)
DESCRIPTION:Ruzaltatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: An Open\, Multicenter Phase II Clinical Trial of SHR-A2009 Combined 
 With Other Anti-tumor Therapies for Perioperative Treatment of Resectable 
 Non-small Cell Lung Cancer.\nEstimated primary completion: 30 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7863167
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895992-2181@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07895992)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Adva
 nced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized 
 Controlled\, Open\, Multicenter Phase III Study\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruzaltatug-rezetecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07895992
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806058-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07806058)
DESCRIPTION:Adebrelimab\, phase 1/2\, Pancreatic Cancer.\nStudy: An Open-La
 bel\, Multicenter\, Phase IB/II Clinical Study of HRS-7172 in Combination 
 With Antitumor Therapy in Participants With Solid Tumors\nEstimated primar
 y completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07806058
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780643-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780643)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-1)\nEstimated primary complet
 ion: 15 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/felcorekibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07780643
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782957-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782957)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Partici
 pants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\nEstimated pr
 imary completion: 6 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/felcorekibart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07782957
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782970-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782970)
DESCRIPTION:Felcorekibart\, phase 3.\nStudy: A Study to Assess the Efficacy
  and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhi
 nosinusitis With Nasal Polyps (CRSwNP)\nEstimated primary completion: 6 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felcorekiba
 rt#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7782970
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915791-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290307
DTEND;VALUE=DATE:20290308
SUMMARY:Felcorekibart: Phase 2 readout est. (NCT07915791)
DESCRIPTION:Felcorekibart\, phase 2\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Assess the Efficacy and Safety of Co-administration o
 f GSK3862995B With GSK5784283 in Adult Participants With Moderate to Sever
 e Chronic Obstructive Pulmonary Disease (COPD)\nEstimated primary completi
 on: 7 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fel
 corekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07915791
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708441-452@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:HRS-1780: Phase 2/3 readout est. (NCT07708441)
DESCRIPTION:HRS-1780\, phase 2/3.\nStudy: A Trial of HRS-1780 in Participan
 ts With Uncontrolled Hypertension or Resistant Hypertension.\nEstimated pr
 imary completion: April 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/hrs-1780#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07708441
URL:https://assetmemo.bio/drug/hrs-1780#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232875-11069@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:HRS-4642: Phase 3 readout est. (NCT07232875)
DESCRIPTION:HRS-4642\, phase 3\, Pancreatic Cancer.\nStudy: HRS 4642 Inject
 ion Combined With AG Versus Placebo Combined With AG Therapy in First-Line
  Advanced or Metastatic Pancreatic Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4642#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07232
 875
URL:https://assetmemo.bio/drug/hrs-4642#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782996-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290504
DTEND;VALUE=DATE:20290505
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07782996)
DESCRIPTION:Felcorekibart\, phase 3\, Asthma.\nStudy: A Study to Investigat
 e the Efficacy and Safety of GSK5784283 Compared With Placebo in Participa
 nts With Uncontrolled Asthma (PERSIST ASTHMA-2)\nEstimated primary complet
 ion: 4 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felc
 orekibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07782996
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: A Phase IB/II Clinical Study o
 f SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patie
 nts With Advanced Solid Tumors\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06474455
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361484-2260@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Plinabulin: Phase 3 readout est. (NCT07361484)
DESCRIPTION:Plinabulin\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Doce
 taxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non
 -Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN
 -4)\nEstimated primary completion: 1 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/plinabulin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07361484
URL:https://assetmemo.bio/drug/plinabulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780656-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780656)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-2)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780656
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780669-3551@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290720
DTEND;VALUE=DATE:20290721
SUMMARY:Felcorekibart: Phase 3 readout est. (NCT07780669)
DESCRIPTION:Felcorekibart\, phase 3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study to Investigate the Efficacy and Safety of GSK5784283 (Fe
 lcorekibart) Compared With Placebo in Participants With Moderate to Very S
 evere COPD (PERSIST COPD-1)\nEstimated primary completion: 20 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/felcorekibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07780669
URL:https://assetmemo.bio/drug/felcorekibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Colorectal Cancer.\nStudy: A 
 Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizum
 ab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
  Cancer\nEstimated primary completion: September 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229625-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07229625)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Study of SHR-8068 in
  Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus 
 Durvalumab in Combination With Platinum-Containing Chemotherapy as First-l
 ine Treatment for Advanced Biliary Tract Cancer (BTC)\nEstimated primary c
 ompletion: December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07229625
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522151-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07522151)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: Clinical Study of Adebrelimab Th
 erapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal
  Junction Cancer\nEstimated primary completion: December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07522151
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726992-11071@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:SHR-1501: Phase 3 readout est. (NCT07726992)
DESCRIPTION:SHR-1501\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BC
 G in Subjects With Papillary-Only NMIBC\nEstimated primary completion: Dec
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1501#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772
 6992
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126640-9096@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06126640)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Phas
 e III\, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine 
 (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual 
 Invasive Disease Following Neoadjuvant Therapy\nEstimated primary completi
 on: April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06126640
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07419828-452@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:HRS-1780: Phase 3 readout est. (NCT07419828)
DESCRIPTION:HRS-1780\, phase 3\, Chronic Kidney Disease.\nStudy: A Phase II
 I Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment o
 f Patients With Chronic Kidney Disease\nEstimated primary completion: Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-1780#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07419828
URL:https://assetmemo.bio/drug/hrs-1780#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424287-11071@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:SHR-1501: Phase 3 readout est. (NCT07424287)
DESCRIPTION:SHR-1501\, phase 3.\nStudy: A Study of Intravesical SHR-1501 Co
 mbination With BCG Versus Investigator-selected Chemotherapy in Subjects W
 ith BCG-unresponsive NMIBC\nEstimated primary completion: June 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/shr-1501#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07424287
URL:https://assetmemo.bio/drug/shr-1501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07118527-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07118527)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Phase III Study of SHR-A1811 i
 n Combination With Chemotherapy and Adebrelimab in Previously Untreated Pa
 tients With Gastric or Gastroesophageal Junction Adenocarcinoma\nEstimated
  primary completion: October 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07118527
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900789-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07900789)
DESCRIPTION:Adebrelimab\, phase 3\, Pancreatic Cancer.\nStudy: HRS-4642 Com
 bined With Antitumor Agents for the Treatment of Perioperative Pancreatic 
 Cancer\nEstimated primary completion: 30 November 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07900789
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239596-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT07239596)
DESCRIPTION:Adebrelimab\, phase 1/2.\nStudy: Phase Ib/II Clinical Study of 
 SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell
  Carcinom\nEstimated primary completion: December 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07239596
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450976-11072@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:SHR-A1904: Phase 2 readout est. (NCT07450976)
DESCRIPTION:SHR-A1904\, phase 2.\nStudy: A Study of SHR-A1904 in Previous S
 ystemic Treatment Failed Biliary Tract Cancer\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr
 -a1904#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07450976
URL:https://assetmemo.bio/drug/shr-a1904#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679360-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07679360)
DESCRIPTION:Adebrelimab\, phase 3\, Breast Cancer.\nStudy: A Study of Trast
 uzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Cho
 ice of Therapy in Subjects With Residual Triple Negative Breast Cancer\nEs
 timated primary completion: December 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07679360
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349069-11068@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:HRS-8080: Phase 3 readout est. (NCT07349069)
DESCRIPTION:HRS-8080\, phase 3.\nStudy: A Phase III Trial Comparing HRS-808
 0 With Standard Endocrine Therapy in Patients With Intermediate or High Ri
 sk Early Breast Cancer\nEstimated primary completion: December 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/hrs-8080#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07349069
URL:https://assetmemo.bio/drug/hrs-8080#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overex
 pressing Non-squamous Non-small Cell Lung Cancer\nEstimated primary comple
 tion: February 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07896005
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625774-186@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07625774)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Chronic Kidney Disease.\nStu
 dy: Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS
 -7535 Evaluated in Participants With Chronic Kidney Disease\nEstimated pri
 mary completion: May 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07625774
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07894328-9146@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:SHR-6209: Phase 3 readout est. (NCT07894328)
DESCRIPTION:SHR-6209\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Ther
 apy in Patients With Advanced or Metastatic Breast Cancer\nEstimated prima
 ry completion: 30 July 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/shr-6209#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07894328
URL:https://assetmemo.bio/drug/shr-6209#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691762-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07691762)
DESCRIPTION:Adebrelimab\, phase 3.\nStudy: A Study of TACE in Combination W
 ith SHR-8068\, Adebrelimab\, and Bevacizumab Versus TACE in Participants W
 ith Incurable Hepatocellular Carcinoma\nEstimated primary completion: Sept
 ember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7691762
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071714-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07071714)
DESCRIPTION:Adebrelimab\, phase 2.\nStudy: A Phase II Study of SHR-8068 Inj
 ection in Combination With Anti-tumor Therapies in Colorectal Cancer\nEsti
 mated primary completion: October 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07071714
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879145-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Notiretatug rezetecan: Phase 2/3 readout est. (NCT06879145)
DESCRIPTION:Notiretatug rezetecan\, phase 2/3.\nStudy: Clinical Study on th
 e Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebre
 limab (SHR-1316)\nEstimated primary completion: December 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06879145
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417554-2064@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT06417554)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A2102
  With or Without Antitumor Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: 31 December 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06417554
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454720-2166@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT07454720)
DESCRIPTION:Adebrelimab\, phase 2/3.\nStudy: A Clinical Study of Adebrelima
 b in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Ther
 apy for Locally Advanced Rectal Cancer\nEstimated primary completion: Nove
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 454720
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183189-2181@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07183189)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib 
 for First-line Treatment in EGFR-mutated\, Advanced or Metastatic NSCLC\nE
 stimated primary completion: November 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07183189
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
